EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON LIVER FAT CONTENT AND ABDOMINAL ADIPOSE TISSUE IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3 MRI)

被引：0
|
作者：
Gastaldelli, A. [1 ]
Cusi, K. [2 ]
Lando, L. Fernandez [3 ]
Bray, R. [3 ]
Brouwers, B. [3 ]
Rodriguez, A. [3 ]
机构：
[1] CNR, Inst Clin Physiol, Cardiometab Risk Unit, Pisa, Italy
[2] Univ Florida, Div Endocrinol Diabet & Metab, Gainesville, FL USA
[3] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP030 / #8
引用
收藏
页码：A37 / A37
页数：1
相关论文
共 50 条
  • [1] Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI)
    Gastaldelli, A.
    Cusi, K.
    Lando, L. Fernandez
    Bray, R.
    Brouwers, B.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 219 - 220
  • [2] Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    Gastaldelli, Amalia
    Cusi, Kenneth
    Fernandez Lando, Laura
    Bray, Ross
    Brouwers, Bram
    Rodriguez, Angel
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06): : 393 - 406
  • [3] Changes in abdominal fat and clinical/analytical parameters in tirzepatide- or insulin degludec-treated patients with type 2 diabetes (SURPASS-3 MRI)
    Gastaldelli, A.
    Cusi, K.
    Fernandez Lando, L.
    Bray, R.
    Torcello-Gomez, A.
    Brouwers, B.
    Rodriguez, A.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S288 - S289
  • [4] Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Insulin Degludec (SURPASS-3)
    Yu, M.
    Bray, R.
    Brown, K.
    Lando, L. Fernandez
    Rodriguez, A.
    Boye, K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [5] EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON GLYCEMIC CONTROL CAPTURED WITH CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3 CGM)
    Battelino, T.
    Bergenstal, R.
    Rodriguez, A.
    Lando, L. Fernandez
    Bray, R.
    Tong, Z.
    Brown, K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A37 - A38
  • [6] Effect of tirzepatide versus insulin degludec on glycaemic control captured with continuous glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM)
    Battelino, T.
    Bergenstal, R.
    Rodriguez, A.
    Lando, L. Fernandez
    Bray, R.
    Tong, Z.
    Brown, K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 244 - 244
  • [7] Tirzepatide reduces muscle fat infiltration relative to insulin deglucec in people with type 2 diabetes (SURPASS-3 MRI)
    Sattar, N.
    Linge, J.
    Neeland, I. J.
    Leinhard, O. Dahlqvist
    Lando, L. Fernandez
    Bray, R.
    Rodriguez, A.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S3 - S4
  • [8] Changes in liver and abdominal fat in tirzepatide-treated patients achieving normoglycaemia in the SURPASS-3 MRI substudy
    Rodriguez, A.
    Cusi, K.
    Gastaldelli, A.
    Nicolay, C.
    Torcello-Gomez, A.
    Lando, L. Fernandez
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S333 - S333
  • [9] The Effect of Tirzepatide vs. Insulin Degludec on Post-meal Glucose Control in Patients with Type 2 Diabetes (SURPASS-3 CGM)
    Battelino, Tadej
    Johnson, Jennal
    Katz, Michelle
    Bray, Ross
    Xue, Jie
    Brown, Katelyn
    DIABETES, 2023, 72
  • [10] Changes in Liver and Abdominal Fat in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 MRI Substudy
    Rodriguez, Angel
    Cusi, Kenneth
    Gastaldelli, Amalia
    Nicolay, Claudia
    Torcello-Gomez, Amelia
    Lando, Laura Fernandez
    DIABETES, 2023, 72
12345